Avacta Group Plc (AIM:AVCT)
London
· Delayed Price · Currency is GBP · Price in GBX 67.50
-3.50 (-4.93%)
At close: Mar 6, 2026
Avacta Group Revenue
Avacta Group had revenue of 56.00K GBP in the half year ending June 30, 2025, a decrease of -99.53%. This brings the company's revenue in the last twelve months to 113.00K, down -103.69% year-over-year. In the year 2024, Avacta Group had annual revenue of 113.00K, down -96.04%.
Revenue
113.00K
Revenue Growth
-103.69%
P/S Ratio
2,612.82
Revenue / Employee
748.34
Employees
151
Market Cap
295.25M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 113.00K | -2.74M | -96.04% |
| Dec 31, 2023 | 2.85M | -6.80M | -70.47% |
| Dec 31, 2022 | 9.65M | 6.71M | 228.22% |
| Dec 31, 2021 | 2.94M | 797.00K | 37.17% |
| Dec 31, 2020 | 2.14M | -1.75M | -44.89% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Jul 31, 2019 | Pro | Pro | Pro |
| Jul 31, 2018 | Pro | Pro | Pro |
| Jul 31, 2017 | Pro | Pro | Pro |
| Jul 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PureTech Health | 4.66M |
| Scancell Holdings | 4.71M |
| Oxford Biomedica | 151.21M |
| 4basebio | 1.78M |
| Bioventix | 13.12M |
| Oxford Nanopore Technologies | 223.90M |
| Faron Pharmaceuticals Oy | 1.14M |
| hVIVO | 54.47M |
Avacta Group News
- 1 year ago - Avacta Provides Business Update for the First Quarter of 2025 Outlining Progress Against Strategic Objectives - GlobeNewsWire
- 1 year ago - Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors - GlobeNewsWire